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Brien Riley, PhD 
Associate Professor 
Department of Psychiatry 
 
 
 
 The opioid receptors and their endogenous ligands have long been implicated in a variety 
of traits including addiction, impulsive behaviors and substance dependence.  Using phenotypic 
measurements collected from the IASPSAD, data from a latent class analysis and data from a 
SNP array and additional genotyping assays, association and regression tests were performed to 
determine the effects of common SNPs encoded in the genes of the opioid receptors and ligands 
on various traits relating to alcohol dependence.  Although only one SNP can be reported as 
significant for substance dependence within alcoholics, there were a few results approaching 
significance that may offer some insight into variation within alcoholism.   
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Introduction 
 
Epidemiology of Alcoholism 
 The impact of alcoholism, defined either as alcohol dependence (AD) or alcohol abuse 
(AA), is prevalent in the United States and throughout the world.  An estimated 3.81% of 
American adults suffer from AD and 4.65% from AA, according to data from the National 
Epidemiological Survey of Alcohol and Related Conditions (NESARC), a nationally 
representative survey conducted 2001-2002 sponsored by the National Institute of Alcohol 
Abuse and Alcoholism (NIAAA) (Grant et al, 2004b).  There are also social impacts, the most 
prominent being traffic incidents.  70% of people in alcohol-related crashes could meet criteria 
for AD, and most of these individuals will have never had prior arrests or treatment (NIAAA, 
2009).  A recent government report shows that despite a 7.5% drop men still outnumber women 
4:1 in drunken driving arrests, but arrests of women have increased 28.8% (National Highway 
Traffic Safety Administration, 2009).  The implications for the individual’s health are no less 
dramatic.  In 2006 there were over 22,000 alcohol-induced deaths, excluding accidents and 
homicides, and there were over 13,000 alcohol-induced liver disease deaths (Heron et al, 2009).  
Chronic excessive use of alcohol can also alter cellular biochemistry and damage the organs.   
Clinical and Genetic Etiology 
 Alcoholism is a recognized psychiatric illness, diagnosed through criteria listed in the 
Diagnostic and Statistical Manual (DSM) of Mental Disorders series (see Table 1).  Currently 
under the DSM-IV AD and AA are mutually exclusive of each other, with AD seen as a more 
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severe form of alcohol use disorder marked by high tolerance, compulsion to drink, and 
withdrawal symptoms (American Psychiatric Association, 1994). 
Table 1.  Abbreviated DSM-IV criteria for alcohol dependence. 
 Maladaptive use of alcohol leading to significant clinical problems.  
Individual endorses 3 or more criteria within the same 12-month period: 
1 Tolerance to alcohol and its effects 
2 Suffers from withdrawal or continues use to relieve withdrawal 
3 Drinking larger amounts for longer periods than intended 
4 Persistent desire or unsuccessful efforts to reduce drinking 
5 Great effort spent to continue drinking 
6 Highest priority given to drinking 
7 Continued drinking despite knowledge of consequences 
 
 In addition, alcoholism is also recognized as a multifactorial disease.  Studies generally 
agree that heritability for AD is 50-60%.  Inheritance of alcoholism, like other psychiatric 
diseases, has not followed Mendelian patterns.  The most likely genetic cause is the sum of 
modest effects from many genetic loci, possibly contributing more so to intermediate 
phenotypes, and these effects can be mediated by particular environmental exposures (Kendler et 
al, 2006; Mayfield et al, 2008).  Polymorphisms in genes of ethanol metabolism, including 
alcohol dehydrogenase (ADH) and the downstream aldehyde dehydrogenase (ALDH) genes (Po-
Hsiu et al, 2007; Chen WJ, 1996), can affect an individual’s risk.  Variants in metabolic genes 
directly impact tolerance and turnover of metabolites and thus increase risk of alcoholism by 
allowing for increased drinking or lower risk if metabolic side effects are aversive.  Numerous 
candidate genes, notably those in neurotransmitter systems, have also been implicated.  
Environmental factors also contribute to the condition, including through interactions with 
genetic susceptibilities.  An early age of drinking (before 15) is the strongest predictor of AD, 
especially within seven years of first use (Grant and Dawson, 1998; Anthony and Petronis, 
1995).  Half of all those who meet criteria for AD in their lifetime do so by the age of 21 and 
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two-thirds by the age of 25 (Hingson et al, 2006).  Social environment can impact the initiation 
of drinking.  In one twin study, alcohol use among adolescents was found to be associated with 
friends who drank and had delinquent behavior—more so the effect was seen among friends of 
the opposite sex, and girls seemed to be more susceptible to these social influences (Dick et al, 
2007a). After adjusting for family history, adverse experiences in childhood and adolescence 
(violence, disruption of the typical family dynamic, etc.) seem to be associated with earlier age 
of onset for drinking and increases risk for alcohol dependence (Rothman et al, 2008; Pilowsky 
et al, 2009). 
Comorbidity  
Alcohol dependence typically does not present by itself.  Twin studies suggest genetic 
overlap in the etiology of psychiatric diseases may be partly responsible for the co-occurrence of 
other conditions with AD (Kendler et al, 2006).  Internalizing phenotypes (depression and 
anxiety) as well as externalizing phenotypes (antisocial personality/conduct disorders and 
substance use disorders) are commonly comorbid with alcoholism (Stinson et al, 2005; Grant et 
al, 2004b; Goldstein et al, 2007).   
Other substance use disorders are the most common comorbid features of AD.  Data from 
the NESARC indicate that 1.1% of the general populace suffers from comorbid alcohol and other 
substance use, and those with specific drug use disorders are extremely likely to be alcoholic as 
well (Stinson et al, 2005).  The National Survey of Substance Abuse Treatment Services reports 
that 18% of all individuals in US substance abuse treatment facilities in 2006 were treated for 
alcohol use alone, but 46% were being treated for both alcohol and substance use (Substance 
Abuse & Mental Health Services Administration, 2007).  This comorbidity is associated with a 
more severe form of AD with greater contribution from genetic susceptibility (Dick et al, 2007b).  
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Comorbid individuals are likely to suffer more from mood, anxiety or personality disorders and 
have an earlier onset of the illness (Stinson et al, 2005; Arnaout B and Petrakis IL, 2008; Di 
Sclafani et al, 2007).   
Studying Alcohol-Related Traits 
Even though the DSM-IV provides an excellent diagnostic tool, it presents some 
limitations due to the underlying complexities of alcohol dependence.  The DSM-IV only 
provides binary (yes-no) information for both the presence of the disease itself and of the 
symptoms.  Severity of the symptoms and the disease are not considered, and neither are other 
important features such as age of earliest drinking and onset, amount of drinking, factors 
contributing to initiation of drinking or comorbid conditions.  Thus, in conjunction with DSM-IV 
criteria it is also helpful to study other phenotypes strongly related to alcoholism.  Quantitative 
phenotypes may provide insight because they are continuous traits that are also more powerful. 
Various methods have been produced over the decades for collecting quantitative data 
related to alcoholism, and two tools in particular have proven to be adept in reliably obtaining 
phenotypic information.  The Self-Rating of the Effects of Alcohol (SRE) provides an attempt to 
find an alternative approach to determining an individual’s level of response to alcohol without 
requiring them to drink (Schuckit et al, 1997).  It utilizes a self report that asks the number of 
drinks required to feel any of a defined number of effects induced by alcohol at three particular 
time points:  the first five times the person drank alcohol, the period of his or her heaviest 
drinking, and within the recent 3 months (Schuckit et al, 1997).  Additionally, the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA) is a comprehensive psychiatric 
interview intended to assess an encompassing list of traits in AA, AD and related psychiatric 
disorders in adults (Bucholz KK, 1994).  Based on well-validated items used in previous 
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psychiatric research interviews and following DSM-III-R criteria, the SSAGA can be used to 
address comorbid conditions by distinguishing their symptoms from those of alcoholism and 
assess age of onset, drinking patterns and severity (Bucholz KK, 1994).   
Opioid Receptor System 
Research has been focusing on genetic susceptibility of AD within genes involved in 
neurotransmission.  Ethanol and other substances of abuse are thought to elicit dependence via 
aberration of the brain’s reward pathways (Koob and Le Moal, 2008).  In particular, the 
dopamine and gamma aminobutyric acid (GABA) systems are thought to play a major role in the 
development of alcohol dependence, and studies have used therapeutic drugs targeting a number 
of neural receptor systems in the treatment of the disease (Heinz et al, 2009; Garbutt, 2009).  
Because ethanol can diffuse across the plasma membrane and can pass the blood-brain barrier, it 
has the potential to directly and indirectly impact neurotransmitter systems such as the opioid 
receptor system, which has long been implicated in alcohol dependence.  This system classically 
consists of three main receptors named the mu, delta and kappa receptors, their corresponding 
genes being OPRM1, OPRD1 and OPRK1.  The genes proopiomelanocortin (POMC), 
proenkephalin (PENK) and prodynorphin (PDYN) encode, respectively, the endogenous ligands 
of the receptors.  The proprotein products of the ligand genes are post-translationally cleaved to 
generate several peptides:  beta-endorphin, adrenocorticotropin hormone (ACTH) and alpha-
melancocyte stimulating hormone (alpha-MSH) from POMC, methionine (Met)-enkephalin and 
leucine (Leu)-enkephalin from PENK, and dynorphin A, dynorphin B and alpha-neoendorphin 
from PDYN.  Also included in the system is a fourth opioid-like receptor encoded by OPRL1, 
which shares much homology to the other receptors.  Its endogenous ligand, nociceptin, is 
processed from pronociceptin (PNOC). 
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Although this neural system is part of a complex system of interactions with other 
proteins and receptors that still are not completely understood, the general function of the 
receptors is.  Extracellular loops and the N-terminal domain determine receptor selectivity for 
ligands (Kieffer and Evans, 2009).  Receptors couple to inhibitory G proteins that inhibit 
adenylyl cyclase, which also inhibits production of cAMP, but also enact on ion channels and 
MAP kinase pathways, perturbances of which are thought to accompany chronic activation of the 
receptors (Childers 1991; Christie MJ 2009).  Activation of the receptors is also known to cause 
downstream effects on other neurotransmitter systems.  Most notably, they act on the mesolimbic 
dopamine pathway, a major component in the reward pathway centered in the ventral tegmental 
area and nucleus accumbens.  Mu and delta receptor activation lead to increased dopamine levels 
while kappa and OPRL1 signaling leads to decreased dopamine release (Spanagel et al, 1992; 
Devine et al, 1993; Koizumi et al, 2004).  While OPRK1 has been shown to counter the effects 
of OPRM1 and OPRD1, it appears that the signaling effects of OPRL1 is distinct from the three 
main receptors.   
Studies in HEK-293 and neuroblastoma cells seem to indicate that opioid receptors could 
homodimerize or heterodimerize with each other if receptors are co-expressed (Gomes et al, 
2000; Gomes et al, 2004; Wang et al, 2005).  Furthermore, there is evidence to indicate that there 
is some form of interaction between opioid and cannabinoid receptors to modulate signaling 
(Bushlin I, in print; Pacheco et al, 2009; Anand et al, 2009) that appears to be signal cross-talk 
although direct interaction between receptors has not been ruled out.  Additional studies suggest 
that opioid receptors may dimerize with other neurotransmitter receptors to affect receptor 
regulation (Pfeiffer et al, 2002; Jordan et al, 2003, Pfeiffer et al, 2003).  These interactions may 
be important in opioid receptor modulation of addiction.   
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The opioid system is known to be involved in the development of tolerance, withdrawal 
and addiction, including having a role in the dependence and reward response to opiates, 
cannabis-related substances, cocaine, stimulants and ethanol (Bodnar RJ, in print; Kreek et al, 
2009; Prisinzano et al, 2005; Maldonado et al, 2002).  The system is also involved in pain 
sensation, reinforcing effects of reward and the modulation of biological impulses such as sexual 
activity, thermoregulation and feeding (Bodnar RJ, in print).  Receptor activity and ligand 
expression are increasingly being associated with mood and behavior.  OPRD1 knockout mice 
exhibit hyperlocomotion and higher anxiety while OPRM1 knockout mice exhibited the opposite 
effects (Filliol et al, 2000).  PENK knockouts also exhibited behavioral abnormalities including 
increased aggressiveness in males and higher anxiety (Konig et al, 1996).  Opioid receptors and 
peptides have also been implicated in impulsive behaviors including gambling, sex addiction and 
eating disorders.  It is suspected that the opioid system mediates behavioral responses through 
effects on the reward pathway.  For example, when performing a gambling task men given 
naloxone (an opioid receptor antagonist) rated high-magnitude rewards less highly and rated 
negative outcomes as more aversive (Predrag et al, 2008).  Receptor activation in the nucleus 
accumbens has been shown to induce feeding and hedonic feeding behaviors, particularly for 
highly palatable foods (Baldo and Kelley, 2007; Pecina and Berridge, 2000).  
Ethanol and The Opioid Receptor System 
Ethanol exposure has been seen to affect opioid receptor and ligand expression.  Ethanol 
induces higher density of mu and delta receptors as well as release of beta-endorphin in areas of 
the mesolimbic dopamine pathway (Jarjour et al, 2009; Rosin et al, 2003; Gianoulakis et al, 
1996).  Ethanol also seems to cause various up- and downregulation of PDYN in different 
regions of the brain, but some of these changes seem to be delayed and long-lasting even after 
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cessation of ethanol exposure (Jarjour et al, 2009, Przewlocka et al, 1992; Gulya et al, 1993).  
There is also suggestion that ethanol retards kappa receptor density overall and reduces POMC 
mRNA in the hypothalamus (Rosin et al, 2003; Scanlon et al, 1992).  Individuals at higher risk 
for alcoholism (i.e. family history) tend to have lower basal plasma beta-endorphin levels, yet 
they also have a more pronounced release of beta-endorphin after exposure to ethanol 
(Gianoulakis et al, 1996).  Post-mortem brains of alcoholics seem to indicate a reduced 
expression of PNOC mRNA in the hippocampus, as well (Kuzmin et al, in print).  Naltrexone, an 
opioid antagonist primarily of the mu receptor, has long been shown to curb drinking habits and 
cravings in alcoholic patients (Volpicelli et al, 1992), further implicating the opioid system in 
alcoholism.   
There have been a number of studies into the genetics of the opioid receptor system and 
their possible role in alcoholism.  Much of the genetic work has focused on OPRM1, in part 
because it is a large gene with many available markers, and largely into the functional variant 
known as A118G or Asn40Asp.  Research has been inconsistent as to genetic contributions of 
OPRM1 to alcohol dependence, particularly the Asn40Asp variant (Kohnke 2008).  There is 
evidence from the Collaborative Study on the Genetics of Alcoholism that SNPs in OPRK1 and 
PDYN are associated with AD, but no associations were found with OPRM1, OPRD1, PENK or 
POMC for AD or illicit drug dependence (Xuei et al, 2006; Xuei et al, 2007).  Meanwhile, 
another SNP association study indicated genetic contribution of OPRD1 and OPRK1 to both 
alcohol and other substance dependence, although the sample sizes were small for other 
substance dependence (Zhang et al, 2008).  These studies represent a trend of mixed results for 
larger-scale SNP association studies of the opioid genes and alcohol dependence.  Little research 
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has gone into OPRL1 or PNOC, but a recent study found an association between rs6010718 in 
OPRL1 and AD (Huang et al, 2008).     
Aim 
The aim of this project is to test for associations between genetic variants in the opioid 
receptor system and alcohol dependence.  Regression and association tests were used to test for 
effects of common SNP variants within the receptor and ligand genes on severity of alcohol-
related traits and presence of other substance dependence. 
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Methods 
 
Irish Affected Sib Pair Study of Alcohol Dependence Genotyping was performed on DNA 
samples collected from the Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD).  
The IASPSAD has been described in detail elsewhere (Prescott et al, 2005).  In brief, from 1998 
through 2002 participants were recruited from hospitals and in-patient community centers in the 
Republic of Ireland and in Northern Ireland.  Probands were considered if they met DSM-IV 
criteria for AD and if their grandparents had been born in Ireland, Northern Ireland, Britain, 
Scotland or Wales.  Consenting participants and those parents and siblings who also consented 
were interviewed by trained staff for demographic information, lifetime history of AD and other 
comorbid conditions, alcohol-related traits and other features.  Diagnosis of AD was confirmed 
using a modified form of the SSAGA, shortened to reduce assessment time.  The interviews 
showed high reliability based on agreement between the reports from each family member.  
DNA from blood draws was also collected.  Control samples for the study came largely from the 
Northern Ireland Blood Transfusion Service as well as the national police force and army 
reserves of the Republic.  Controls were not included if they reported a history of heavy drinking 
or problematic use of alcohol.  Due to time and funding constraints, they were not interviewed 
for additional information.   
Addiction Array Previously a genotyping array had been performed as a candidate gene study 
designed on the Illumina Goldengate platform, and it is described elsewhere (Hodgkinson et al, 
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2008).  In brief, SNPs from 130 candidate genes, the eight opioid genes among them, for 
alcoholism and addiction phenotypes were selected from NCBI Human Genome Build 35.1, 
including 5 kb-upstream and 1 kb-downstream flanking regions (generally sufficient in size to 
cover regulatory regions).  Genotype data for these SNPs in the African Yoruban population 
were downloaded from the HapMap Project, public release #18 (www.hapmap.org) and were 
used to construct haplotypes in SNPHAP (http://www-
gene.cimr.cam.ac.uk/clayton/software/snphap.txt).  Due to the age of the African population, a 
greater number of SNPs would be required to adequately cover the selected genomic regions, 
and this coverage would then provide enough information across other population samples.  
Functional SNPs (non-synonymous and splice site mutations) were force included.  A subset of 
genetically independent samples from the IASPSAD was sent to Dr. David Goldman’s 
Laboratory of Neurogenetics, NIAAA, to be genotyped on the array.  500 ng of DNA from each 
sample were used per array, and duplicate samples were sent as a measure of genotyping 
accuracy that provided a replication rate of 99.4%.  Processing prior to PCR was performed 
using a TECAN liquid handling robot, and the arrays were imaged using an Illumina Beadstation 
GX500.  Data was analyzed using GenCall v6.2.0.4 and GTS Reports software v5.1.2.0 
(Illumina).   
Identifying Additional Tagging SNPs Because the array used SNPs selected from the African 
population, the results did not provide complete coverage in the Irish sample.  Some SNPs were 
either of very low frequency or monomorphic in the IASPSAD subset.  Enough time had also 
passed since the array that more SNPs had been identified and confirmed.  Genotype data in the 
CEPH population (Caucasians in Utah) was downloaded from the HapMap Project (March 2008 
release, build 36) using the most recent build with available data for the regions each gene lied 
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within.  The CEPH data was viewed with the TAGGER function in HaploView 4.0 
(http://broadinstitute.org/haploview/haploview, Broad Institute) to determine the number of 
additional SNPs needed for more complete coverage of the opioid genes in a Caucasian 
population.  Default settings for TAGGER were used (r2 = 0.8; MAF= 0.2) because they set a 
high threshold for identifying tagging SNPs and allow selection of SNPs expected to be common 
in a Caucasian population.  PDYN, a small gene with few previously selected loci, did not yield 
additional results at the default settings, so the MAF threshold was lowered to 0.1 to see if 
additional tagging SNPs would be produced.  Flanking regions were excluded from this search 
due to observed linkage disequilibrium in HaploView between some of these regions and 
neighboring genes (see Figure 1) and in part to the expense of the genotyping assays.  The 
exception was for one SNP in OPRL1 because it lied in a bidirectional promoter the receptor 
gene shared with RGS19.  Only the 79-kb region containing the exons for the MOR-1 isoform of 
OPRM1 was included in the search because the remaining 3′ end of the gene overlaps with PIP3-
E.  SNPs that had already been used in the array, that were tagged by SNPs in the array, or that 
did not tag other SNPs were disregarded. 
Genotyping Additional Tag SNPs Genotyping of the additional SNPs was conducted using 
Taqman assays (Applied Biosystems, Foster City, CA).  The assays use a chemical quencher to 
suppress the fluorescence of the dyes VIC and FAM, which are incorporated into the primers 
specific to each allele in a SNP assay.  During primer extension the quencher is released, and 
fluorescence of either or both dyes determines the alleles present in a DNA sample.  Dry plates 
were made with 1 ng DNA per individual per well on 384-well plates using genetically 
independent samples from a subset of the IASPSAD.  Negative controls were included in each 
plate, but duplicates were not because of limited space on the plates.  Assay mix was prepared as 
 
  14 
OPRD1 
  
OPRL1 
 
PNOC 
 
OPRM1 
 
Figure 1. LD plots from HaploView 4.0 of opioid genes in linkage disequilibrium with neighboring genes.  
Blue bars represent the relative position of the target gene, and white bars represent positions of neighboring 
genes.  In OPRL1, neighboring genes were adjacent to the receptor gene.  OPRM1 partially overlapped with a 
neighboring gene.  The plot for PNOC is misleading as no SNPs of MAF=0.2 lied within the region between 
the ligand gene and the neighboring gene.  POMC, PENK, PDYN and OPRK1 did not appear to have 
problems with LD. 
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follows:  PCR Buffer to 1X (Invitrogen), MgCl2 to 2.1 mM (Invitrogen), total dNTPs to 41.3 µM 
(Invitrogen and Bioline), TaqMan assay to 1X, Taq polymerase to 1U/150 µL (Invitrogen and 
Bioline) and PCR-grade water to sufficient volume.  5 µL of assay mix was distributed to each 
well using the epMotion 5075 liquid handling robot manufactured by Eppendorf.  Plates were 
sealed and centrifuged for 1 min at 1600 rpm to pool contents to the bottoms of the wells.  Plates 
were then placed on Mastercycler ep thermocyclers from Eppendorf to follow the lab’s standard 
PCR protocol (see Table 2). 
 The standard protocol failed to amplify the OPRL1 promoter SNP because of high GC 
content (~72%), so a procedure similar to Frey’s “slowdown PCR” (Frey et al, 2008), which is 
effective for GC-rich regions, was employed.  The PCR assay mix was prepared as follows:  
PCR Buffer to 1X, MgCl2 to 1.7 mM, total dNTPs to 80 µM, TaqMan assay to 1X, Taq 
polymerase to 1U/150 µL, and PCR-grade water to sufficient volume.  Though Frey used 7-
deaza-2′-guanosine, it was avoided here because of the additional cost and time to order.  PCR 
steps were also modified (see Table 2). 
 
Table 2.  PCR protocols for TaqMan assays.  
 Initial 
Heating 
 
Melting  
Primer 
Annealing 
 
Extension 
 
Reps 
95 º C 92 º C 60 º C 72 º C Standard 
PCR 2 min 15 sec 1 min 5 min 
2nd-4th steps repeated to 
total of 40 cycles 
      
95 º C 95 º C 65 º C 72 º C Modified 
PCR 5 min 30 sec 45 sec 90 sec 
2nd-4th steps repeated to 
total of 50 cycles 
   
 
Plates were spun after PCR for 1 min at 1600 rpm.  Dye fluorescence was measured by 
the Analyst AD plate reader and CriterionHost v2.01.00 software developed by Molecular 
Devices.  Plots of the VIC versus FAM fluorescences for each well formed three distinguishable 
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“clusters,” representing the three possible genotypes for each SNP.  If necessary, additional PCR 
cycles were performed in order to better distinguish genotypes from the fluorescence readings.  
Points within each “cluster” were scored the proper genotype according to the FAM:VIC 
fluorescence ratios and the allele that each dye represented.  Negative controls were not scored 
and individuals with failed (locus did not amplify) or ambiguous (points not clearly part of one 
cluster) genotypes were considered missing.  As with the addiction array, the more common 
allele was scored as “1” and the less common (minor) allele as “2.”  
Quality Control of Dataset Genotypic data for common to both the addiction array and the 
additional SNPs were used for analysis.  SNPs were included if their respective genotyping rates 
were > 90%.  SNPs with a MAF < 0.03 or with Hardy-Weinberg equilibrium p-value < 0.001 
were removed.  Subject samples passed quality control if their respective genotyping rates were 
> 80%. 
SNP Binary Association Tests in PLINK SNP association tests were performed in the free 
software PLINK (version 1.06, http://pngu.mgh.harvard.edu/~purcell/plink/) using the –-assoc 
command.  This command produces odds ratios for each SNP for a binary condition.  First a 
case-control association test was performed alcohol dependence.  As a comparison, another case-
control association test for AD was performed on controls and only those cases featuring 
comorbid substance dependence (definite and probable).  In addition, 10,000 max (T) 
permutations were run with each association test using the –-mperm command.  Permutation 
testing has been shown to be a conservative method to handle corrections for multiple tests, and 
this particular method gives significance values for each SNP but accounts for testing the other 
SNPs within the set.   
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Regression Testing in PLINK Set-based regression tests between SNP genotypes and 
quantitative traits were performed in PLINK using the –-set-test option.  Set-based 
analyses test independent SNPs within a single set (i.e. gene) rather than testing all of them 
simultaneously to reduce the number of required test corrections.  SNPs were assigned to sets 
according to their respective genes.  Pairwise genotypic correlations were used in PLINK to 
identify SNPs that may have been in high LD.  The defaults for the command (--indep-
pairwise) were used (r2 = 0.8, D′ = 0.50) in a window of 15 SNPs, shifting every 3 for each 
pass—this allowed for detection of SNPs in strong LD with each other.  The TAGGER function 
in HaploView was also used, considering the same thresholds, to see if the algorithms would 
produce similar results.  The same SNPs marked for exclusion were identified in both PLINK 
and TAGGER.  One SNP which PLINK originally marked for exclusion was switched with a 
proxy marked for inclusion due to differences in genotyping rates (see Results).  Sex and age at 
interview were covaried out. 
Linear regression tests were performed in two sets of traits.  Phenotypic information for 
indicators of severity of AD (age of onset, symptom count and maximum number of drinks ever 
consumed in 24 hours) were run in the first set of tests.  The second set of tests consisted of 
measures of the physiological aspects of AD (withdrawal, tolerance and initial sensitivity to 
alcohol).  The traits were divided as such to analyze the physiological and non-physiological 
traits separately.      
A set-based logistic regression test was performed on substance dependence.  This test 
compared AD cases comorbid for other substance dependence (definite and probable) to AD 
cases who had reported using at least one substance other than alcohol but had no other 
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substance dependence.  Those who had reported never using any other substances were excluded 
because their risk for other substance dependence cannot be determined.   
Additionally, Dr. Carol Prescott and Nikki Sintov from the Department of Psychology, 
University of Southern CaliforniaLinear provided information from a latent class analysis (LCA) 
performed on affected individuals in the IASPSAD (results to be published).  Briefly, 12 
indicators including personality traits, mood disorder and drug dependences were used because 
of evidence of their etiological overlap with AD.  Using Mplus version 4.1, the number of 
classes needed was determined by comparing the fit improvement associated with the addition of 
each class.  It was found that three classes were the most likely result (p=<0.0001), as had been 
found in previous analyses in the literature.  These three classes were termed mild, depressed and 
severe, and they are described below.  Individuals were assigned to their respective class 
according to their highest probability of belonging, determined by item endorsement patterns.   
The LCA provided interesting information in that it included demarcations in differences of 
substance dependence while also including information from other traits available from the 
IASPSAD interviews.  Set-based linear regression of SNP genotypes to class membership was 
performed in PLINK as well as separate linear regressions of the probabilities of individuals 
belonging to each class. 
10,000 max (T) permutations were performed along with each set-based regression test. 
Selection of Phenotypes for Analysis The phenotypes chosen for analysis were either taken 
directly from responses in the IASPSAD interviews or calculated from the responses.  These 
phenotypes, the LCA results and substance dependence were chosen because of the role of the 
opioid receptor system in the development of tolerance and addiction to substances of 
dependence, in the reward response to substances of dependence and in impulsive behaviors. 
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 The first group of phenotypes in the linear regression analyses are indicators of severity 
of AD.  As explained above, an early age of onset for alcohol dependence (ADONSET) as well 
as other substance dependence is associated with a more severe affected status.  Symptom count 
(ADSX) is a direct measure of severity as those more strongly affected tend to endorse more of 
the DSM-IV criteria for AD.  Greater severity of symptoms, particularly withdrawal, is also 
associated with a more severe form of the illness.  The maximum number of alcoholic drinks 
reportedly ever consumed in 24 hours (MAX24) is a proxy for tolerance; those who are able to 
drink more will not as readily succumb to the physiological effects of heavy drinking.  More so, 
the role of the opioid system in the stimulation to consume food suggests it may affect the 
amount of alcohol a person imbibes by motivating individuals to drink more.  Alcoholic drinks 
were defined from a standard measure as 12 ounces of beer, 4 ounces of wine or 1.5 ounces of 
spirits. 
 The phenotypes in the second group were calculated measurements of physiological 
responses to ethanol exposure.  Tolerance (TOLMX) and withdrawal (WITHDR_FS) were 
included because of evidence that this system impacts these features in both alcohol and other 
substances.  As a baseline measure of response, initial sensitivity (ISENS) is both related to the 
development of AD and serves as an indicator to tolerance later on.  ISENS and TOLMX were 
previously measured (Po-Hsiu et al, 2006) from answers to the SRE, which asked about the 
number of drinks a person required to feel effects from alcohol (dizziness, stumbling, passing 
out, etc.).  ISENS was determined by dividing the number of drinks “the first five times [he or 
she] ever drank” by the number of effects endorsed, so a higher score indicates reduced 
sensitivity.  Similarly, TOLMX was determined for “the period when [he or she] drank the 
most,” but a higher score indicates greater tolerance.  Withdrawal (WITHDR_FS) was 
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previously calculated based on ten withdrawal symptoms in the SSAGA (hands trembling, 
unable to sleep, feeling anxious, depressed or irritable, racing pulse, sweating, nausea, feeling 
physically weak, headaches, hallucinations, and restlessness) (Po-Hsiu et al, 2006).  A factor 
analysis conducted in Mplus weighted which of the 10 symptoms each individual endorsed such 
that scores reflected the varying contribution of each symptom to withdrawal severity.   
 Substance dependence was assessed because of the relationship between comorbid 
substance dependence and AD severity and because of the implication of the opioid receptors in 
use of a number of substances, including alcohol.  Both definite (at least 3 criteria from DSM-IV 
endorsed) and probable (2 criteria from DSM-IV endorsed) dependence were considered to 
include as much information as possible.   
The three LCA classes were termed mild, depressed and severe.  The mild class consisted 
of individuals with the lowest scores for all 12 indicators.  The severe group was composed of 
those scoring the highest for most of the indicators and who were most affected by drug 
dependence and had polysubstance use.  The depressed class was an intermediate class that was 
not as severely affected as those in the severe class but ranked highest for depression.  These 
classes were included for analysis because of the affects of substance dependence in class 
membership and because there is a growing body of evidence that the opioid receptors and 
endogenous ligands may be involved in mood disorders, personality traits and other indicators 
included in the LCA.  
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Figure 2. Symptom endorsement probabilities (SEPs) for the three classes.  D=depressed, S=severe, M=mild.  
Dep=dependence, ASPD=antisocial personality disorder.  Figure was supplied by Nikki Sintov and Dr. Carol 
Prescott of the University of Southern California.
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Results 
 
TaqMan Assays The additional SNPs for which assays were ordered are listed (see Table 3).  For 
examples of a typical plot of the dye fluorescences refer to Figure 1 (Appendix A).  An example 
of the failure of the standard protocol to amplify the OPRL1 locus along with an example of the 
modified protocol, which had drastic improvements in distinguishing genotypes, is available (see 
Figure 2, Appendix A). 
Quality Control of Dataset Initially there were a total of 93 SNPs:  81 from the addiction array 
and 12 of the additional tagging SNPs.  10 were removed for not meeting quality control 
standards:  3 SNPs had a 0% genotyping rate, and 7 SNPs had MAFs < 0.005 in this sample set.  
The remaining 83 SNPs (71 from the addiction array and 12 additional tagging SNPs) met the 
Hardy-Weinberg requirement.  A list of the remaining SNPs is presented below (see Table 3). 
Initially, the sample set contained 1054 subjects, of which 637 (60.4%) were male and 
414 (39.3%) were female with 3 of unknown sex.  Of these, 545 (51.7%) were cases and 509 
(48.3%) were controls.  On average the genotyping rate per SNP was 94.3% (ranging 0.0-
98.8%), and the average genotyping rate per individual was 94.3% (ranging 5.4-96.8%).  26 
individuals (8 cases and 18 controls) were subsequently removed for not meeting quality control 
criteria. 18 of the removed samples had genotyping rates below 70%, and 1 case and 1 control 
were borderline to but below an 80% genotyping rate.  After quality control, 1028 samples 
remained in the dataset.  618 (60.1%) were male and 407 (39.6%) were female with 3 of 
unknown sex.  537 were cases (52.2%) and 491 (47.8%) were controls.  The average genotyping
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rate per SNP in the dataset then was 97.3% (ranging 90.7-98.8%), and the average genotyping 
rate per individual was 98.7% (80.7-100.0). Of those remaining in the dataset, 2 controls and 1 
case were borderline but above the required 80% genotyping rate.  
 
Table 3.  List of SNPs surviving quality control measures.  Minor allele frequencies reflect the frequencies of 
the alleles least common in the cases.  (†) demarks SNPs additional to those from the addiction array. 
Locus (Chr 
#) 
Base 
Position 
Minor Allele* 
(Freq. Cases, 
Controls) 
HWE  
P-value 
Genotyping 
Rate 
OPRD1 (1)     
rs16837697 29007133 C (0.031, 0.038) 1.000 98.4% 
rs2236861 29012343 A (0.259, 0.247) 0.161 97.8% 
rs678849 29017775 C (0.454, 0.449) 1.000 97.9% 
rs204055 29031960 T (0.451, 0.453) 0.801 98.1% 
rs2236857 29034196 C (0.259, 0.241) 0.934 98.1% 
rs2298896 29038725 G (0.319, 0.315) 0.386 97.9% 
rs3766951 29042146 C (0.321, 0.318) 0.251 98.2% 
rs529520 29047533 C (0.447, 0.450) 0.613 97.3% 
rs499062† 29047639 C (0.211, 0.231) 0.075 93.6% 
rs2234918 29062184 T (0.460, 0.439) 0.899 97.9% 
rs4654327 29062725 G (0.483, 0.478) 0.950 98.3% 
rs204076 29062977 T (0.391, 0.388) 0.036 98.0% 
     
POMC (2)     
rs6713532 25238337 C (0.217, 0.216) 0.459 97.9% 
rs3769671 25243657 C (0.030, 0.034) 1.000 98.6% 
rs6545976 25248154 T (0.047, 0.043) 0.144 98.5% 
rs6719226 25249516 G (0.047, 0.043) 0.138 97.8% 
     
OPRM1 (6)     
rs1799971 154402490 G (0.100, 0.119) 0.872 96.9% 
rs510769 154403712 T (0.255, 0.262) 0.625 97.8% 
rs3778151 154435373 C (0.169, 0.163) 0.572 97.6% 
rs483021 154439021 G (0.045, 0.051) 0.499 98.8% 
rs562859† 154456266 C (0.329, 0.351) 0.467 90.7% 
rs660756 154457127 G (0.335, 0.352) 0.945 98.6% 
rs650245 154470384 A (0.096, 0.095) 1.000 98.7% 
rs558025 154483657 G (0.237, 0.264) 0.024 98.5% 
rs10485058 154486907 G (0.162, 0.134) 0.805 98.4% 
rs548339 154502491 T (0.335, 0.358) 0.890 98.5% 
rs569284 154506022 C (0.044, 0.051) 1.000 98.2% 
rs2236256 154520132 C (0.486, 0.464) 0.571 96.7% 
rs1918760 154523859 C (0.385, 0.369) 0.463 97.5% 
rs2281617 154529113 T (0.134, 0.131) 0.684 97.5% 
rs6941251 154529669 C (0.408, 0.425) 0.653 97.9% 
rs1998220 154548120 A (0.412, 0.421) 0.847 98.0% 
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Locus (Chr 
#) 
Base 
Position 
Minor Allele* 
(Freq. Cases, 
Controls) 
HWE  
P-value 
Genotyping 
Rate 
OPRM1 (6)     
rs9322451 154564353 A (0.167, 0.180) 0.232 98.6% 
rs9479791 154571206 T (0.105, 0.124) 0.356 98.3% 
rs790266 154583595 T (0.429, 0.456) 0.849 96.8% 
rs2272381 154584183 G (0.115, 0.154) 0.077 97.7% 
rs9371781 154593899 C (0.327, 0.300 0.514 97.8% 
rs6935927 154602029 C (0.420, 0.423) 0.405 98.3% 
rs4314511 154607027 G (0.142, 0.164) 0.184 98.5% 
     
PNOC (8)     
rs2722897 28229116 A (0.109, 0.116) 0.531 98.5% 
rs1563945 28230805 C (0.182, 0.167) 0.280 97.6% 
rs7825480 28234932 G (0.181, 0.169) 0.666 97.7% 
rs2614095 28240910 A (0.433, 0.453) 0.184 98.4% 
rs351776 28247225 A (0.454, 0.447) 0.571 98.4% 
rs4732849† 28249765 T (0.316, 0.287) 0.194 93.8% 
rs351784 28253666 G (0.140, 0.154) 1.000 98.7% 
rs4732850 28254635 A (0.100, 0.117) 0.628 98.1% 
     
OPRK1 (8)     
rs3802280 54303552 A (0.080, 0.102) 0.127 98.7% 
rs3802281 54303716 C (0.147, 0.176) 0.007 98.6% 
rs7817710 54305368 T (0.071, 0.097) 0.303 98.5% 
rs7016275 54312323 G (0.067, 0.073) 0.226 98.3% 
rs16918909 54312587 G (0.084, 0.088) 1.000 98.2% 
rs7016778 54312658 T (0.147, 0.153) 0.806 98.4% 
rs1365097† 54315344 C (0.239, 0.230) 0.858 94.2% 
rs6473797 54315535 C (0.239, 0.228) 0.257 98.6% 
rs6473798† 54315658 T (0.303, 0.296) 0.758 92.8% 
rs7826614 54319979 A (0.199, 0.180) 0.474 95.7% 
rs10504151 54320793 G (0.119, 0.103) 0.874 97.5% 
rs3808627 54327355 T (0.168, 0.158) 0.421 97.8% 
     
PENK (8)     
rs1437277 57519288 T (0.265, 0.231) 0.867 98.6% 
rs1975285 57521236 G (0.266, 0.232) 0.803 98.3% 
rs2609998 57522588 A (0.436, 0.461) 0.226 95.7% 
     
PDYN (20)     
rs910080† 1908226 G (0.211, 0.207) 0.100 94.0% 
rs10485703 1908313 G (0.110, 0.099) 0.739 98.1% 
rs6045824 1909977 C (0.111, 0.103) 0.325 98.1% 
rs6035222 1911413 A (0.122, 0.119) 0.767 97.9% 
rs1418038† 1914947 C (0.145, 0.144) 0.198 95.8% 
rs13037430† 1915049 T (0.038, 0.046) 0.692 96.7% 
rs2235751 1917934 G (0.202, 0.214) 1.000 97.8% 
rs2235753† 1918547 G (0.091, 0.099) 1.000 95.9% 
rs2281285 1920460 C (0.100, 0.108) 0.735 97.0% 
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Locus (Chr 
#) 
Base 
Position 
Minor Allele* 
(Freq. Cases, 
Controls) 
HWE  
P-value 
Genotyping 
Rate 
PDYN (20)     
rs1997794 1922858 C (0.322, 0.325) 0.195 95.9% 
rs3830064 1923679 C (0.107, 0.110) 0.746 98.3% 
rs7272891† 1924818 G (0.101, 0.108) 1.000 93.5% 
rs10854244† 1925045 T (0.217, 0.221) 1.000 96.7% 
rs6136667 1926301 C (0.111, 0.112) 1.000 95.3% 
     
OPRL1 (20)     
rs6011280† 62175584 C (0.303, 0.296) 0.121 91.3% 
rs6090041 62183120 G (0.308, 0.293) 0.654 96.2% 
rs6512305 62186714 G (0.456, 0.483) 0.660 97.2% 
rs6090043 62188374 T (0.452, 0.476) 0.802 98.8% 
rs6011291 62193155 G (0.098, 0.096) 0.374 97.8% 
rs7271530 62198359 C (0.453, 0.486) 0.900 98.2% 
rs6089789 62202436 T (0.097, 0.102) 0.163 97.6% 
 
SNP Association Tests All individuals were included in the case-control association test, but 
only 166 (30.9%) of the cases were included in the comorbid-control association test.  Two SNPs 
(rs2272381 from OPRM1 and rs7817710 from OPRK1, p=0.009 and p=0.031, respectively) 
initially returned with significant p-values from the case-control association; however, they did 
not pass permutation testing (lowest permuted p-value=0.420).  In the comorbid-control 
association test, there were no significant results to be reported.  
Regression Tests of Phenotypes 17 SNPs from the addiction array were excluded for high 
genotypic correlations to other SNPs.  As mentioned in Methods, one SNP that PLINK had 
originally marked for exclusion was replaced by a correlated SNP that had been kept for 
inclusion.  Because the call rate for rs6136667 in PDYN was lower than the two SNPs it was 
correlated with (95.3% compared to 97.0% and 98.3%), it replaced rs3830064, arbitrarily 
chosen, for exclusion from analysis. 
Because information was not collected on the controls in the IASPSAD, all analyses 
performed used genotypes only from the AD probands.  For both ADONSET and age at which 
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participants were interviewed, there were wide ranges in ages from young adults to the elderly.  
The mean age of onset was relatively young (26.2 years, SD=8.9), as is typically seen.  Of the 
537 affected individuals, the majority of them endorsed all 7 symptoms (357, 66.5%), and only 
33 (6.2%) endorsed fewer than 5 symptoms.  353 individuals were included for analysis of 
dependent versus non-dependent substance use.  Of those 166 (47.0%) were classified as 
dependent on other substances and 187 (53.0%) had used drugs but were not dependent. There 
were 14 (4.0%) individuals designated as dependent who scored only for probable dependence.  
All 537 AD subjects were included in the analyses on the LCA classes.  Of them 299 (55.7%) 
were placed in the depressed class, 59 (11.0%) in the severe class and 179 (33.3%) in the mild 
class.  264 (49.1%) individuals presented probabilities of at least 88% of being in their 
designated class.  No individual had a probability less than 50% of being in their assigned class. 
Several SNPs returned with initial significance in a number of phenotypes, but only one 
passed permutation testing (see bold entries in Tables 5a-5d).  One copy of the minor allele of 
rs6719226 in POMC, one of the array SNPs, increased the risk for an alcoholic to also develop 
dependence on other substances (OR=2.993, p=0.010, permuted p=0.018) (see Table 5).  Caution 
should be taken with this result, though, because of the lower frequency of the minor allele 
(MAF=0.088) among the cases in the sample for this analysis.  Of the 353 individuals used in the 
dependent versus non-dependent substance use phenotype regression test, there were only 3 
individuals homozygous for the minor allele and only 25 who were heterozygous.   
There were four SNPs which approached significance after permutation testing.  Two 
SNPs in PDYN suggested a trend between copies of the minor allele and increased percentage of 
individuals belonging to the mild class in the LCA—and, in effect, a decreasing percentage of 
those belonging to the depressed class (percentage of those in the severe class did not change).    
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There were also two SNPs in the delta receptor which suggested a trend with increasing ISENS 
scores (meaning decreased initial sensitivity to alcohol).          
 
Table 4.  SNP in POMC surviving permutation testing.  Logistic regression was performed on dependence, so 
odds ratio (OR) is presented instead of Beta.  Other SNPs approaching significance from permutation testing 
are presented.  The effects sizes represent those for the minor allele. 
SNP Gene Locus 
Position 
Phenotype  
Associated 
BETA (95% CI) P-Value 
(Permuted 
P-Value) 
rs6719226 POMC 5′ (~4.5 
kb) 
Dependence 2.993 (OR) (1.301-
6.888)  
0.010 
(0.018) 
      
rs910080 PDYN 3′ UTR Class Placement 0.018 (0.041-0.304) 0.010 
(0.056) 
rs1997794 PDYN 5′ (<1 
kb) 
Class Placement 0.134 (0.023-0.245) 0.018 
(0.056) 
rs529520 OPRD1 Intron 1 ISENS 0.399 (0.024-0.774) 0.038 
(0.060) 
rs3766951 OPRD1 Intron 1 ISENS 0.5722 (0.180-
0.964) 
0.004 
(0.060) 
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Table 5a. Uncorrected p-values from linear regression of severity-related phenotypes of AD with effects sizes (BETA) and 95% confidence intervals.  
SNPs with missing information were excluded from analysis on the basis of high genotypic correlation with other SNPs.  (†) demarks SNPs additional to 
those from the addiction array.  Bold entries indicate those that reported as significant but did not pass corrective tests. 
Locus  
(Chr #) Base Position ADONSET 
ADONSET Beta (95% 
CI) ADSX ADSX Beta (95% CI) MAX24 MAX24 Beta (95% CI) 
OPRD1 (1)        
rs16837697 29007133 0.767 
-0.385  
(-2.930,2.161) 0.206 
-0.208  
(-0.531,0.114) 0.847 
-0.605  
(-6.751,5.542) 
rs2236861 29012343 0.876 
-4.74 (-6.062, 
-3.421) 0.488 0.179 (0.012,0.347) 0.903 14.940 (11.750,18.130) 
rs678849 29017775 0.059 0.441 (0.375,0.507) 0.792 
-0.012 (-0.020, 
-0.004) 0.681 
-0.109  
(-0.268,0.050) 
rs204055 29031960       
rs2236857 29034196 0.909 
0.080  
(-0.933,1.094) 0.452 
0.046  
(-0.083,0.174) 0.621 
-0.153  
(-2.609,2.303) 
rs2298896 29038725       
rs3766951 29042146 0.673 
-4.754 (-6.078, 
-3.43) 0.083 0.191 (0.023,0.359) 0.148 15.000 (11.790,18.210) 
rs529520 29047533 0.108 0.437 (0.372,0.503) 0.075 
-0.012 (-0.020, 
-0.004) 0.233 
-0.107  
(-0.267,0.053) 
rs499062† 29047639 0.139 
0.859  
(-0.030,1.748) 0.739 
0.015  
(-0.098,0.129) 0.812 
-0.455  
(-2.622,1.712) 
rs2234918 29062184       
rs4654327 29062725 0.739 
-4.812 (-6.125, 
-3.499) 0.257 
0.1811 
(0.01296,0.3492) 0.437 15.020 (11.820,18.210) 
rs204076 29062977 0.193 0.445 (0.380,0.511) 0.458 
-0.012 (-0.020, 
-0.004) 0.944 
-0.113  
(-0.272,0.047) 
        
POMC (2)        
rs6713532 25238337 0.215 
-0.059  
(-1.063,0.946) 0.683 
0.049  
(-0.078,0.176) 0.912 0.612 (-1.811,3.036) 
rs3769671 25243657 0.234 
-4.739 (-6.059, 
-3.418) 0.725 0.183 (0.015,0.350) 0.031 14.890 (11.700,18.070) 
rs6545976 25248154       
rs6719226 25249516 0.117 0.442 (0.376,0.508) 0.331 
-0.012 (-0.020, 
-0.003) 0.926 
-0.100  
(-0.260,0.059) 
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Locus  
(Chr #) Base Position ADONSET 
ADONSET Beta (95% 
CI) ADSX ADSX Beta (95% CI) MAX24 MAX24 Beta (95% CI) 
OPRM1 (6)        
rs1799971 154402490 0.234 0.201 (-0.729,1.131) 0.448 0.104 (-0.013,0.222) 0.905 1.656 (-0.587,3.898) 
rs510769 154403712 0.201 
-4.739 (-6.059,  
-3.418) 0.786 0.184 (0.017,0.351) 0.520 14.960 (11.780,18.150) 
rs3778151 154435373 0.204 0.441 (0.375,0.507) 0.695 
-0.012 (-0.020, 
-0.003) 0.984 -0.101 (-0.260,0.058) 
rs483021 154439021 0.687 0.733 (-0.160,1.625) 0.691 0.103 (-0.010,0.216) 0.652 1.311 (-0.842,3.464) 
rs562859† 154456266 0.580 
-4.695 (-6.014, 
-3.376) 0.721 0.184 (0.016,0.351) 0.037 14.800 (11.620,17.980) 
rs660756 154457127       
rs650245 154470384 0.232 0.441 (0.375,0.507) 0.053 
-0.012 (-0.020, 
-0.003) 0.779 -0.098 (-0.257,0.061) 
rs558025 154483657 0.636 0.842 (-0.272,1.956) 0.696 0.024 (-0.116,0.164) 0.254 0.327 (-2.369,3.022) 
rs10485058 154486907 0.245 
-4.776 (-6.118, 
-3.433) 0.480 0.178 (0.010,0.347) 0.208 14.950 (11.700,18.200) 
rs548339 154502491 0.646 0.441 (0.374,0.507) 0.340 
-0.012 (-0.021, 
-0.004) 0.188 -0.084 (-0.245,0.077) 
rs569284 154506022 0.492 0.151 (-0.739,1.041) 0.216 -0.065 (-0.178,0.047) 0.977 0.848 (-1.290,2.985) 
rs2236256 154520132 0.553 
-4.721 (-6.042, 
-3.401) 0.277 0.187 (0.019,0.354) 0.953 14.850 (11.680,18.020) 
rs1918760 154523859 0.875 0.440 (0.375,0.506) 0.956 
-0.012 (-0.020, 
-0.004) 0.474 -0.103 (-0.262,0.055) 
rs2281617 154529113 0.206 0.630 (-0.317,1.577) 0.147 -0.046 (-0.166,0.075) 0.672 0.082 (-2.193,2.358) 
rs6941251 154529669       
rs1998220 154548120       
rs9322451 154564353 0.364 
-4.752 (-6.078, 
-3.427) 0.362 0.184 (0.016,0.352) 0.842 14.710 (11.530,17.900) 
rs9479791 154571206 0.432 0.440 (0.374,0.507) 0.720 
-0.012 (-0.020, 
-0.004) 0.782 -0.097 (-0.256,0.062) 
rs790266 154583595 0.567 0.711 (-0.412,1.833) 0.439 -0.030 (-0.173,0.113) 0.261 0.153 (-2.552,2.858) 
rs2272381 154584183 0.923 
-4.707 (-6.028, 
-3.386) 0.385 0.187 (0.019,0.355) 0.356 14.830 (11.640,18.010) 
rs9371781 154593899 0.209 0.441 (0.375,0.506) 0.232 
-0.012 (-0.021, 
-0.004) 0.433 -0.102 (-0.260,0.057) 
rs6935927 154602029 0.439 
-1.563  
(-4.137,1.010) 0.353 0.059 (-0.268,0.386) 0.158 6.854 (0.659,13.050) 
rs4314511 154607027 0.441 -4.727 (-6.044,-3.410) 0.326 0.185 (0.018,0.352) 0.705 14.940 (11.770,18.110) 
  30 
Locus  
(Chr #) Base Position ADONSET 
ADONSET Beta (95% 
CI) ADSX ADSX Beta (95% CI) MAX24 MAX24 Beta (95% CI) 
PNOC (8)        
rs2722897 28229116 0.025 0.440 (0.375,0.506) 0.960 
-0.012 (-0.020,-
0.004) 0.441 -0.106 (-0.264,0.052) 
rs1563945 28230805       
rs7825480 28234932 0.822 1.632 (-0.403,3.667) 0.319 0.128 (-0.130,0.387) 0.242 -0.232 (-5.134,4.670) 
rs2614095 28240910 0.964 -4.744 (-6.061,-3.426) 0.440 0.185 (0.018,0.352) 0.608 14.850 (11.670,18.020) 
rs351776 28247225 0.509 0.442 (0.376,0.507) 0.857 
-0.012 (-0.020,-
0.004) 0.778 -0.103 (-0.261,0.056) 
rs4732849† 28249765 0.700 -0.935 (-2.472,0.602) 0.873 0.075 (-0.119,0.270) 0.582 -0.226 (-3.925,3.474) 
rs351784 28253666 0.926 -4.686 (-6.016,-3.357) 0.988 0.190 (0.022,0.358) 0.504 14.910 (11.710,18.110) 
rs4732850 28254635 0.767 0.440 (0.373,0.506) 0.801 
-0.012 (-0.020,-
0.003) 0.465 -0.102 (-0.262,0.058) 
        
OPRK1 (8)        
rs3802280 54303552       
rs3802281 54303716 0.993 -0.668 (-1.690,0.354) 0.846 -0.018 (-0.148,0.112) 0.467 -0.813 (-3.285,1.659) 
rs7817710 54305368 0.541 -4.771 (-6.092,-3.45) 0.597 0.183 (0.015,0.351) 0.274 14.890 (11.700,18.090) 
rs7016275 54312323 0.276 0.440 (0.375,0.506) 0.422 
-0.012 (-0.020,-
0.004) 0.482 -0.109 (-0.268,0.050) 
rs16918909 54312587 0.458 -0.762 (-1.936,0.412) 0.447 0.030 (-0.120,0.179) 0.982 -0.030 (-2.872,2.813) 
rs7016778 54312658 0.110 -4.785 (-6.101,-3.469) 0.337 0.185 (0.017,0.352) 0.083 15.020 (11.830,18.210) 
rs1365097† 54315344 0.990 0.444 (0.378,0.509) 0.979 
-0.012 (-0.020,-
0.004) 0.556 -0.112 (-0.271,0.047) 
rs6473797 54315535 0.965 0.434 (-1.679,2.548) 0.752 0.054 (-0.214,0.323) 0.499 -1.174 (-6.277,3.93) 
rs6473798† 54315658 0.331 -4.734 (-6.052,-3.415) 0.775 0.185 (0.017,0.352) 0.375 14.970 (11.780,18.150) 
rs7826614 54319979 0.300 0.441 (0.376,0.507) 0.658 
-0.012 (-0.020,-
0.004) 0.087 -0.110 (-0.269,0.049) 
rs10504151 54320793 0.743 -0.277 (-1.259,0.704) 0.968 0.022 (-0.100,0.145) 0.426 2.507 (0.163,4.850) 
PENK (8)        
rs3808627 54327355 0.473 -4.913 (-6.294,-3.532) 0.680 0.205 (0.033,0.3767) 0.616 15.200 (11.900,18.490) 
rs1437277 57519288       
rs1975285 57521236 0.749 0.452 (0.382,0.521) 0.897 
-0.012 (-0.021,-
0.004) 0.072 -0.071 (-0.237,0.010) 
rs2609998 57522588 0.197 -0.913 (-2.407,0.581) 0.618 0.188 (-0.002,0.377) 0.153 0.520 (-3.098,4.137) 
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Locus  
(Chr #) Base Position ADONSET 
ADONSET Beta (95% 
CI) ADSX ADSX Beta (95% CI) MAX24 MAX24 Beta (95% CI) 
PDYN (20)        
rs910080† 1908226 0.335 -4.699 (-6.018,-3.380) 0.760 0.192 (0.025,0.360) 0.128 15.020 (11.820,18.210) 
rs10485703 1908313       
rs6045824 1909977       
rs6035222 1911413 0.660 0.443 (0.377,0.509) 0.822 
-0.012 (-0.021,-
0.004) 0.092 -0.109 (-0.268,0.050) 
rs1418038† 1914947 0.532 0.245 (-0.768,1.258) 0.488 -0.026 (-0.154,0.103) 0.089 1.422 (-1.020,3.863) 
rs13037430† 1915049 0.724 -4.757 (-6.082,-3.433) 0.240 0.185 (0.017,0.353) 0.354 14.740 (11.540,17.930) 
rs2235751 1917934 0.366 0.442 (0.376,0.508) 0.351 
-0.012 (-0.020,-
0.003) 0.518 -0.108 (-0.267,0.051) 
rs2235753† 1918547 0.994 0.715 (-0.489,1.919) 0.960 0.055 (-0.010,0.208) 0.981 1.871 (-1.035,4.778) 
rs2281285 1920460       
rs1997794 1922858 0.438 -4.677 (-5.997,-3.357) 0.633 0.189 (0.021,0.357) 0.050 15.100 (11.910,18.290) 
rs3830064 1923679 0.465 0.439 (0.374,0.505) 0.121 
-0.012 (-0.020,-
0.004) 0.433 -0.113 (-0.272,0.046) 
rs7272891† 1924818 0.735 -0.216 (-1.140,0.708) 0.750 0.057 (-0.060,0.174) 0.949 1.500 (-0.730,3.729) 
rs10854244† 1925045 0.794 -4.717 (-6.037,-3.397) 0.495 0.181 (0.0140,0.349) 0.316 14.860 (11.680,18.050) 
rs6136667 1926301       
        
OPRL1 (20)        
rs6011280† 62175584 0.852 0.442 (0.376,0.508) 0.946 
-0.012 (-0.021,-
0.004) 0.329 -0.114 (-0.273,0.045) 
rs6090041 62183120 0.387 0.749 (-1.384,2.883) 0.752 0.172 (-0.010,0.443) 0.300 0.0752 (-5.090,5.240) 
rs6512305 62186714       
rs6090043 62188374       
rs6011291 62193155       
rs7271530 62198359 0.264 -4.733 (-6.053,-3.413) 1.000 0.183 (0.015,0.350) 0.205 15.060 (11.870,18.260) 
rs6089789 62202436 0.087 0.445 (0.379,0.510) 0.896 
-0.012 (-0.020,-
0.003) 0.265 -0.111 (-0.270,0.049) 
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Table 5b.  Uncorrected p-values from linear regression of physiological phenotypes of AD with effects sizes (BETA) and 95% confidence intervals.  
SNPs with missing information were excluded from analysis on the basis of high genotypic correlation with other SNPs.  (†) demarks SNPs additional to 
those from the addiction array.  Bold entries indicate those that reported as significant but did not pass corrective tests. 
Locus (Chr 
#) 
Base 
Position ISENS ISENS Beta (95% CI) TOLMX TOLMX Beta (95% CI) 
WITHDR_
FS 
WITHDR_FS Beta (95% 
CI) 
OPRD1 (1)        
rs16837697 29007133 0.507 -0.369 (-1.461,0.722) 0.193 1.430 (-0.720,3.581) 0.102 -0.221 (-0.485,0.043) 
rs2236861 29012343 0.245 0.256 (-0.175,0.687) 0.672 0.184 (-0.668,1.037) 0.734 0.167 (0.030,0.305) 
rs678849 29017775 0.385 0.168 (-0.211,0.546) 0.532 0.238 (-0.509,0.985) 0.902 -0.004 (-0.011,0.003) 
rs204055 29031960       
rs2236857 29034196 0.104 0.353 (-0.071,0.776) 0.037 0.887 (0.057,1.717) 0.662 0.018 (-0.087,0.124) 
rs2298896 29038725       
rs3766951 29042146 0.004 0.572 (0.180,0.964) 0.054 0.765 (-0.012,1.542) 0.031 0.168 (0.030,0.306) 
rs529520 29047533 0.038 0.399 (0.024,0.774) 0.229 0.455 (-0.286,1.196) 0.074 -0.004 (-0.010,0.003) 
rs499062† 29047639 0.640 0.112 (-0.356,0.580) 0.336 0.452 (-0.468,1.372) 0.771 -0.006 (-0.099,0.087) 
rs2234918 29062184       
rs4654327 29062725 0.922 -0.019 (-0.394,0.357) 0.832 0.080 (-0.661,0.821) 0.772 0.171 (0.033,0.308) 
rs204076 29062977 0.618 -0.102 (-0.500,0.297) 0.810 -0.096 (-0.878,0.686) 0.174 -0.004 (-0.010,0.003) 
        
POMC (2)        
rs6713532 25238337 0.868 0.040 (-0.433,0.512) 0.497 -0.323 (-1.255,0.608) 0.434 0.023 (-0.081,0.128) 
rs3769671 25243657 0.052 1.049 (-0.007,2.105) 0.033 2.273 (0.192,4.355) 0.413 0.173 (0.035,0.310) 
rs6545976 25248154       
rs6719226 25249516 0.872 -0.070 (-0.923,0.783) 0.993 -0.007 (-1.687,1.672) 0.357 -0.004 (-0.011,0.003) 
        
OPRM1 (6)        
rs1799971 154402490 0.858 -0.059 (-0.700,0.583) 0.514 0.424 (-0.850,1.698) 0.385 0.106 (0.010,0.203) 
rs510769 154403712 0.478 0.156 (-0.275,0.587) 0.994 -0.003 (-0.853,0.847) 0.074 0.173 (0.036,0.310) 
rs3778151 154435373 0.841 0.051 (-0.446,0.548) 0.962 0.024 (-0.958,1.007) 0.114 -0.003 (-0.010,0.004) 
rs483021 154439021 0.639 0.212 (-0.673,1.097) 0.767 0.265 (-1.482,2.011) 0.849 0.085 (-0.008,0.178) 
rs562859† 154456266 0.344 0.183 (-0.196,0.562) 0.910 0.046 (-0.754,0.846) 0.912 0.166 (0.029,0.303) 
rs660756 154457127       
rs650245 154470384 0.957 0.017 (-0.613,0.648) 0.827 -0.139 (-1.388,1.109) 0.039 -0.003 (-0.010,0.004) 
rs558025 154483657 0.401 0.182 (-0.242,0.606) 0.784 -0.117 (-0.950,0.717) 0.119 -0.017 (-0.133,0.100) 
rs10485058 154486907 0.017 -0.614 (-1.118,-0.110) 0.760 0.156 (-0.844,1.156) 0.884 0.167 (0.027,0.307) 
rs548339 154502491 0.474 0.141 (-0.245,0.527) 0.903 4.003 (2.903,5.103) 0.841 -0.003 (-0.010,0.004) 
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Locus (Chr 
#) 
Base 
Position ISENS ISENS Beta (95% CI) TOLMX TOLMX Beta (95% CI) 
WITHDR_
FS 
WITHDR_FS Beta (95% 
CI) 
OPRM1 (6)        
rs569284 154506022 0.821 0.104 (-0.800,1.008) 0.726 0.000 (-0.055,0.055) 0.054 -0.014 (-0.106,0.079) 
rs2236256 154520132 0.233 -0.229 (-0.605,0.147) 0.333 -0.048 (-0.810,0.714) 0.863 0.172 (0.035,0.310) 
rs1918760 154523859 0.852 -0.037 (-0.430,0.355) 0.188 3.995 (2.896,5.094) 0.483 -0.004 (-0.010,0.003) 
rs2281617 154529113 0.079 -0.493 (-1.042,0.056) 0.378 0.001 (-0.054,0.056) 0.156 -0.068 (-0.167,0.030) 
rs6941251 154529669       
rs1998220 154548120       
rs9322451 154564353 0.113 -0.427 (-0.955,0.101) 0.448 0.319 (-1.467,2.105) 0.048 0.173 (0.035,0.311) 
rs9479791 154571206 0.755 -0.102 (-0.739,0.536) 0.072 4.011 (2.908,5.113) 0.468 -0.004 (-0.010,0.003) 
rs790266 154583595 0.522 -0.125 (-0.506,0.256) 0.505 0.001 (-0.054,0.056) 0.860 -0.047 (-0.164,0.070) 
rs2272381 154584183 0.881 -0.045 (-0.636,0.546) 0.316 -0.366 (-1.106,0.374) 0.699 0.169 (0.032,0.307) 
rs9371781 154593899 0.331 -0.202 (-0.609,0.205) 0.520 3.943 (2.851,5.035) 0.645 -0.004 (-0.010,0.003) 
rs6935927 154602029 0.502 -0.130 (-0.510,0.250) 0.459 0.006 (-0.049,0.061) 0.755 -0.112 (-0.380,0.156) 
rs4314511 154607027 0.873 -0.044 (-0.586,0.498) 0.353 -0.518 (-1.287,0.252) 0.896 0.174 (0.036,0.311) 
        
PNOC (8)        
rs2722897 28229116 0.018 0.701 (0.121,1.281) 0.037 3.921 (2.828,5.014) 0.139 -0.004 (-0.011,0.003) 
rs1563945 28230805       
rs7825480 28234932 0.021 0.573 (0.087,1.059) 0.018 0.007 (-0.048,0.062) 0.335 0.100 (-0.112,0.312) 
rs2614095 28240910 0.299 -0.196 (-0.567,0.174) 0.586 -0.489 (-1.575,0.596) 0.854 0.171 (0.033,0.308) 
rs351776 28247225 0.413 0.156 (-0.218,0.530) 0.974 3.997 (2.901,5.094) 0.766 -0.004 (-0.010,0.003) 
rs4732849† 28249765 0.706 -0.077 (-0.476,0.323) 0.278 0.002 (-0.053,0.057) 0.223 0.071 (-0.089,0.231) 
rs351784 28253666 0.249 0.307 (-0.214,0.828) 0.737 0.405 (-0.640,1.451) 0.042 0.171 (0.033,0.309) 
rs4732850 28254635 0.784 0.086 (-0.526,0.697) 0.506 4.008 (2.910,5.105) 0.359 -0.004 (-0.011,0.003) 
        
OPRK1 (8)        
rs3802280 54303552       
rs3802281 54303716 0.641 -0.129 (-0.669,0.412) 0.555 0.000 (-0.055,0.055) 0.391 0.097 (-0.009,0.203) 
rs7817710 54305368 0.984 0.008 (-0.743,0.758) 0.115 1.155 (-0.102,2.412) 0.462 0.179 (0.042,0.316) 
rs7016275 54312323 0.631 -0.191 (-0.968,0.587) 0.760 4.050 (2.954,5.146) 0.985 -0.004 (-0.010,0.003) 
rs16918909 54312587 0.586 -0.190 (-0.874,0.494) 0.852 0.001 (-0.054,0.056) 0.969 0.099 (-0.023,0.221) 
rs7016778 54312658 0.795 -0.072 (-0.618,0.474) 0.863 -0.256 (-1.008,0.496) 0.226 0.174 (0.037,0.311) 
rs1365097† 54315344 0.433 -0.186 (-0.650,0.278) 0.225 3.983 (2.885,5.080) 0.252 -0.004 (-0.011,0.003) 
rs6473797 54315535 0.303 -0.238 (-0.690,0.214) 0.249 0.001 (-0.054,0.056) 0.370 -0.021 (-0.242,0.199) 
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Locus (Chr 
#) 
Base 
Position ISENS ISENS Beta (95% CI) TOLMX TOLMX Beta (95% CI) 
WITHDR_
FS 
WITHDR_FS Beta (95% 
CI) 
OPRK1 (8)        
rs6473798† 54315658 0.495 -0.151 (-0.583,0.282) 0.491 -0.597 (-1.763,0.568) 0.475 0.174 (0.036,0.311) 
rs7826614 54319979 0.164 -0.334 (-0.805,0.136) 0.868 3.976 (2.877,5.075) 0.304 -0.004 (-0.011,0.003) 
rs10504151 54320793 0.056 -0.568 (-1.150,0.013) 0.763 0.000 (-0.055,0.055) 0.808 -0.006 (-0.107,0.095) 
rs3808627 54327355 0.554 0.152 (-0.351,0.655) 0.364 0.265 (-0.542,1.072) 0.598 0.208 (0.066,0.350) 
        
PENK (8)        
rs1437277 57519288       
rs1975285 57521236 0.742 0.074 (-0.365,0.513) 0.386 3.994 (2.898,5.091) 0.837 -0.003 (-0.010,0.004) 
rs2609998 57522588 0.975 -0.006 (-0.379,0.367) 0.815 0.001 (-0.054,0.056) 0.517 0.164 (0.009,0.320) 
        
PDYN (20)        
rs910080† 1908226 0.968 0.009 (-0.428,0.446) 0.506 -0.284 (-1.03,0.467) 0.600 0.176 (0.039,0.313) 
rs10485703 1908313       
rs6045824 1909977       
rs6035222 1911413 0.099 -0.469 (-1.025,0.087) 0.411 3.990 (2.891,5.090) 0.575 -0.004 (-0.011,0.003) 
rs1418038† 1914947 0.111 -0.433 (-0.965,0.098) 0.527 0.000 (-0.055,0.055) 0.850 -0.084 (-0.189,0.021) 
rs13037430
† 1915049 0.084 
0.838 (-0.112,1.788) 
0.721 
-0.508 (-1.576,0.561) 
0.812 
0.179 (0.042,0.317) 
rs2235751 1917934 0.279 0.251 (-0.203,0.706) 0.715 3.988 (2.891,5.084) 0.369 -0.003 (-0.010,0.003) 
rs2235753† 1918547 0.369 -0.284 (-0.903,0.335) 0.397 0.001 (-0.054,0.056) 0.196 0.009 (-0.116,0.135) 
rs2281285 1920460       
rs1997794 1922858 0.891 -0.027 (-0.412,0.358) 0.559 1.219 (0.076,2.361) 0.298 0.174 (0.037,0.312) 
rs3830064 1923679 0.013 0.771 (0.162,1.380) 0.925 3.920 (2.831,5.009) 0.612 -0.004 (-0.011,0.003) 
rs7272891† 1924818 0.264 -0.365 (-1.005,0.275) 0.504 0.009 (-0.046,0.064) 0.260 -0.010 (-0.106,0.086) 
rs10854244
† 1925045 0.338 
0.224 (-0.234,0.682) 
0.804 
1.158 (0.204,2.113) 
0.700 
0.174 (0.037,0.312) 
rs6136667 1926301       
        
OPRL1 (20)        
rs6011280† 62175584 0.260 0.229 (-0.169,0.626) 0.116 3.981 (2.894,5.068) 0.444 -0.004 (-0.010,0.003) 
rs6090041 62183120 0.616 0.107 (-0.309,0.522) 0.964 0.009 (-0.045,0.064) 0.909 0.219 (-0.003,0.441) 
rs6512305 62186714       
rs6090043 62188374       
rs6011291 62193155       
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Locus (Chr 
#) 
Base 
Position ISENS ISENS Beta (95% CI) TOLMX TOLMX Beta (95% CI) 
WITHDR_
FS 
WITHDR_FS Beta (95% 
CI) 
OPRL1 (20)        
rs7271530 62198359 0.393 -0.167 (-0.551,0.216) 0.237 -0.203 (-0.934,0.528) 0.722 0.164 (0.027,0.302) 
rs6089789 62202436 0.262 0.351 (-0.262,0.965) 0.753 3.972 (2.873,5.071) 0.585 -0.003 (-0.010,0.004) 
 
Table 5c.  Uncorrected p-values from linear regression of probabilities of AD individuals belonging to each LCA class with effects sizes (BETA) and 
95% confidence intervals.  SNPs with missing information were excluded from analysis on the basis of high genotypic correlation with other SNPs.  (†) 
demarks SNPs additional to those from the addiction array.  Bold entries indicate those that reported as significant but did not pass corrective tests. 
Locus (Chr 
#) 
Base 
Position 
Depress 
Class 
Depress Class Beta 
(95% CI) 
Severe 
Class  
Severe Class Beta 
(95% CI) 
Mild 
Class  
Mild Class Beta (95% 
CI) 
OPRD1 (1)        
rs16837697 29007133 0.060 -0.116 (-0.237,0.005) 0.037 0.010 (0.006,0.186) 0.727 0.021 (-0.094,0.135) 
rs2236861 29012343 0.947 -0.050 (-0.113,0.013) 0.794 0.078 (0.031,0.125) 0.782 -0.028 (-0.088,0.031) 
rs678849 29017775 0.386 -0.003 (-0.006,0.000) 0.676 -0.010 (-0.013,-0.008) 0.214 0.013 (0.011,0.016) 
rs204055 29031960       
rs2236857 29034196 0.941 -0.002 (-0.050,0.047) 0.174 -0.005 (-0.040,0.031) 0.326 0.006 (-0.039,0.052) 
rs2298896 29038725       
rs3766951 29042146 0.290 -0.051 (-0.114,0.012) 0.227 0.076 (0.028,0.123) 0.868 -0.025 (-0.084,0.035) 
rs529520 29047533 0.637 -0.003 (-0.006,0.000) 0.459 -0.010 (-0.013,-0.008) 0.935 0.013 (0.010,0.016) 
rs499062† 29047639 0.978 -0.019 (-0.062,0.024) 0.822 -0.007 (-0.037,0.025) 0.837 0.026 (-0.015,0.066) 
rs2234918 29062184       
rs4654327 29062725 0.958 -0.046 (-0.109,0.017) 0.790 0.075 (0.028,0.122) 0.794 -0.030 (-0.089,0.030) 
rs204076 29062977 0.705 -0.003 (-0.007,0.000) 0.689 -0.010 (-0.013,-0.008) 0.932 0.014 (0.011,0.017) 
        
POMC (2)        
rs6713532 25238337 0.158 0.002 (-0.046,0.050) 0.306 -0.025 (-0.060,0.011) 0.493 0.023 (-0.023,0.068) 
rs3769671 25243657 0.352 -0.045 (-0.108,0.018) 0.183 0.074 (0.028,0.121) 0.949 -0.029 (-0.089,0.030) 
rs6545976 25248154       
rs6719226 25249516 0.308 -0.003 (-0.007,0.000) 0.110 -0.010 (-0.012,-0.008) 0.862 0.014 (0.011,0.016) 
        
OPRM1 (6)        
rs1799971 154402490 0.085 0.024 (-0.020,0.068) 0.530 -0.020 (-0.054,0.013) 0.186 -0.004 (-0.046,0.038) 
rs510769 154403712 0.362 -0.048 (-0.111,0.014) 0.371 0.076 (0.029,0.123) 0.096 -0.028 (-0.087,0.032) 
rs3778151 154435373 0.272 -0.003 (-0.006,0.000) 0.307 -0.010 (-0.013,-0.008) 0.049 0.014 (0.011,0.017) 
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Locus (Chr 
#) 
Base 
Position 
Depress 
Class 
Depress Class Beta 
(95% CI) 
Severe 
Class  
Severe Class Beta 
(95% CI) 
Mild 
Class  
Mild Class Beta (95% 
CI) 
OPRM1 (6)        
rs483021 154439021 0.399 0.010 (-0.032,0.053) 0.325 -0.012 (-0.043,0.020) 0.908 0.002 (-0.039,0.042) 
rs562859† 154456266 0.267 -0.048 (-0.111,0.015) 0.079 0.074 (0.027,0.120) 0.850 -0.026 (-0.086,0.034) 
rs660756 154457127       
rs650245 154470384 0.053 -0.003 (-0.006,0.000) 0.957 -0.010 (-0.012,-0.008) 0.045 0.014 (0.010,0.016) 
rs558025 154483657 0.372 -0.001 (-0.054,0.052) 0.348 -0.005 (-0.044,0.035) 0.094 0.005 (-0.045,0.056) 
rs10485058 154486907 0.475 -0.044 (-0.108,0.020) 0.429 0.073 (0.026,0.121) 0.894 -0.030 (-0.090,0.031) 
rs548339 154502491 0.990 -0.003 (-0.007,0.000) 0.475 -0.010 (-0.012,-0.008) 0.584 0.014 (0.011,0.017) 
rs569284 154506022 0.277 -0.001 (-0.043,0.041) 0.055 -0.004 (-0.036,0.027) 0.717 0.005 (-0.035,0.046) 
rs2236256 154520132 0.485 -0.045 (-0.108,0.018) 0.292 0.073 (0.027,0.120) 0.932 -0.028 (-0.088,0.031) 
rs1918760 154523859 0.765 -0.003 (-0.007,0.000) 0.747 -0.010 (-0.012,-0.008) 0.947 0.013 (0.010,0.016) 
rs2281617 154529113 0.990 -0.009 (-0.054,0.036) 0.937 0.007 (-0.027,0.040) 0.960 0.001 (-0.041,0.045) 
rs6941251 154529669       
rs1998220 154548120       
rs9322451 154564353 0.799 -0.044 (-0.107,0.019) 0.940 0.072 (0.025,0.118) 0.742 -0.028 (-0.087,0.032) 
rs9479791 154571206 0.418 -0.004 (-0.007,0.000) 0.761 -0.010 (-0.012,-0.008) 0.274 0.014 (0.011,0.016) 
rs790266 154583595 0.441 -0.038 (-0.092,0.015) 0.529 0.021 (-0.019,0.060) 0.190 0.018 (-0.033,0.068) 
rs2272381 154584183 0.602 -0.046 (-0.109,0.017) 0.493 0.073 (0.026,0.119) 0.992 -0.027 (-0.086,0.033) 
rs9371781 154593899 0.872 -0.003 (-0.007,0.000) 0.635 -0.010 (-0.012,-0.008) 0.587 0.013 (0.010,0.0164) 
rs6935927 154602029 0.459 -0.058 (-0.181,0.064) 0.694 0.062 (-0.029,0.153) 0.275 -0.004 (-0.120,0.113) 
rs4314511 154607027 0.136 -0.047 (-0.109,0.016) 0.705 0.075 (0.029,0.122) 0.203 -0.029 (-0.088,0.031) 
        
PNOC (8)        
rs2722897 28229116 0.597 -0.003 (-0.006,0.000) 0.346 -0.010 (-0.013,-0.008) 0.856 0.014 (0.011,0.016) 
rs1563945 28230805       
rs7825480 28234932 0.528 -0.050 (-0.147,0.046) 0.301 0.059 (-0.013,0.130) 0.886 -0.008 (-0.100,0.084) 
rs2614095 28240910 0.339 -0.045 (-0.107,0.018) 0.203 0.073 (0.026,0.119) 0.044 -0.028 (-0.088,0.032) 
rs351776 28247225 0.885 -0.003 (-0.007,0.000) 0.122 -0.010 (-0.012,-0.008) 0.172 0.013 (0.010,0.016) 
rs4732849† 28249765 0.595 0.064 (-0.009,0.137) 0.063 -0.017 (-0.071,0.037) 0.043 -0.047 (-0.116,0.022) 
rs351784 28253666 0.820 -0.045 (-0.108,0.018) 0.904 0.072 (0.026,0.119) 0.737 -0.027 (-0.087,0.033) 
rs4732850 28254635 0.202 -0.003 (-0.007,0.000) 0.054 -0.010 (-0.012,-0.008) 0.873 0.013 (0.010,0.016) 
        
OPRK1 (8)        
rs3802280 54303552       
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Locus (Chr 
#) 
Base 
Position 
Depress 
Class 
Depress Class Beta 
(95% CI) 
Severe 
Class  
Severe Class Beta 
(95% CI) 
Mild 
Class  
Mild Class Beta (95% 
CI) 
OPRK1 (8)        
rs3802281 54303716 0.881 0.023 (-0.026,0.071) 0.993 0.017 (-0.020,0.053) 0.870 -0.039 (-0.085,0.007) 
rs7817710 54305368 0.123 -0.045 (-0.108,0.018) 0.438 0.076 (0.029,0.123) 0.311 -0.032 (-0.091,0.028) 
rs7016275 54312323 0.113 -0.003 (-0.006,0.000) 0.170 -0.010 (-0.013,-0.008) 0.554 0.013 (0.010,0.016) 
rs16918909 54312587 0.569 0.031 (-0.025,0.087) 0.416 0.022 (-0.020,0.064) 0.969 -0.053 (-0.106,0.000) 
rs7016778 54312658 0.058 -0.046 (-0.109,0.017) 0.244 0.076 (0.029,0.123) 0.280 -0.030 (-0.089,0.030) 
rs1365097† 54315344 0.580 -0.003 (-0.006,0.000) 0.733 -0.010 (-0.013,-0.008) 0.754 0.014 (0.011,0.017) 
rs6473797 54315535 0.627 -0.043 (-0.144,0.057) 0.550 0.038 (-0.037,0.113) 0.967 0.006 (-0.090,0.101) 
rs6473798† 54315658 0.801 -0.046 (-0.109,0.016) 0.823 0.075 (0.028,0.122) 0.926 -0.029 (-0.088,0.031) 
rs7826614 54319979 0.243 -0.003 (-0.006,0.000) 0.363 -0.010 (-0.013,-0.008) 0.604 0.014 (0.011,0.016) 
rs10504151 54320793 0.546 0.026 (-0.020,0.073) 0.392 -0.031 (-0.065,0.003) 0.973 0.004 (-0.040,0.048) 
rs3808627 54327355 0.714 -0.040 (-0.105,0.025) 0.292 0.077 (0.029,0.125) 0.661 -0.037 (-0.100,0.025) 
        
PENK (8)        
rs1437277 57519288       
rs1975285 57521236 0.523 -0.004 (-0.007,-0.001) 0.538 -0.010 (-0.012,-0.007) 0.849 0.014 (0.010,0.017) 
rs2609998 57522588 0.679 0.070 (-0.001,0.141) 0.535 -0.001 (-0.055,0.052) 0.354 -0.069 (-0.136,-0.002) 
        
PDYN (20)        
rs910080† 1908226 0.035 -0.047 (-0.110,0.016) 0.346 0.075 (0.028,0.122) 0.003 -0.028 (-0.087,0.032) 
rs10485703 1908313       
rs6045824 1909977       
rs6035222 1911413 0.263 -0.003 (-0.007,0.000) 0.883 -0.010 (-0.013,-0.008) 0.288 0.014 (0.011,0.017) 
rs1418038† 1914947 0.852 -0.022 (-0.070,0.026) 0.404 -0.017 (-0.053,0.019) 0.648 0.039 (-0.007,0.085) 
rs13037430† 1915049 0.578 -0.045 (-0.108,0.018) 0.783 0.075 (0.029,0.122) 0.714 -0.031 (-0.090,0.029) 
rs2235751 1917934 0.250 -0.003 (-0.007,0.000) 0.264 -0.010 (-0.012,-0.008) 0.036 0.013 (0.010,0.016) 
rs2235753† 1918547 0.513 -0.021 (-0.078,0.036) 0.634 0.017 (-0.025,0.060) 0.288 0.004 (-0.051,0.058) 
rs2281285 1920460       
rs1997794 1922858 0.062 -0.048 (-0.111,0.015) 0.603 0.077 (0.030,0.124) 0.017 -0.029 (-0.088,0.031) 
rs3830064 1923679 0.616 -0.003 (-0.007,0.000) 0.082 -0.010 (-0.013,-0.008) 0.057 0.014 (0.011,0.016) 
rs7272891† 1924818 0.316 0.000 (-0.044,0.044) 0.724 -0.012 (-0.045,0.021) 0.181 0.012 (-0.030,0.053) 
rs10854244† 1925045 0.117 -0.047 (-0.110,0.016) 0.420 0.076 (0.029,0.123) 0.023 -0.030 (-0.089,0.030) 
rs6136667 1926301       
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Locus (Chr 
#) 
Base 
Position 
Depress 
Class 
Depress Class Beta 
(95% CI) 
Severe 
Class  
Severe Class Beta 
(95% CI) 
Mild 
Class  
Mild Class Beta (95% 
CI) 
OPRL1 (20)        
rs6011280† 62175584 0.418 -0.003 (-0.006,0.000) 0.838 -0.010 (-0.013,-0.008) 0.306 0.013 (0.010,0.016) 
rs6090041 62183120 0.485 0.056 (-0.045,0.158) 0.205 -0.074 (-0.150,0.001) 0.797 0.018 (-0.079,0.114) 
rs6512305 62186714       
rs6090043 62188374       
rs6011291 62193155       
rs7271530 62198359 0.863 -0.051 (-0.114,0.012) 0.608 0.077 (0.030,0.124) 0.557 -0.026 (-0.086,0.034) 
rs6089789 62202436 0.667 -0.003 (-0.006,0.000) 0.157 -0.010 (-0.013,-0.008) 0.516 0.014 (0.011,0.017) 
 
Table 5d.  Uncorrected p-values from linear regression of class membership of AD cases and from logistic regression of substance dependence in 
alcoholics with effects sizes (BETA for membership, OR for dependence) and 95% confidence intervals.  SNPs with missing information were excluded 
from analysis on the basis of high genotypic correlation with other SNPs.  (†) demarks SNPs additional to those from the addiction array.  Bold entries 
indicate those that reported as significant but did not pass corrective tests (except rs6719226 in POMC). 
Locus (Chr #) Base Position 
Class 
Membership Class Placement Beta (95% CI) Dependence Dependence OR (95% CI) 
OPRD1 (1)      
rs16837697 29007133 0.258 0.178 (-0.131,0.488) 0.537 1.311 (0.555,3.099) 
rs2236861 29012343 0.994 0.066 (-0.094,0.226) 0.835 1.288 (0.812,2.044) 
rs678849 29017775 0.376 0.017 (0.009,0.025) 0.416 0.947 (0.924,0.971) 
rs204055 29031960     
rs2236857 29034196 0.663 0.000 (-0.124,0.123) 0.789 0.962 (0.665,1.390) 
rs2298896 29038725     
rs3766951 29042146 0.563 0.070 (-0.091,0.231) 0.198 1.269 (0.800,2.014) 
rs529520 29047533 0.859 0.017 (0.009,0.025) 0.746 0.947 (0.924,0.971) 
rs499062† 29047639 0.876 0.049 (-0.060,0.158) 0.960 0.875 (0.635,1.206) 
rs2234918 29062184     
rs4654327 29062725 0.749 0.055 (-0.105,0.216) 0.711 1.324 (0.832,2.106 ) 
rs204076 29062977 0.991 0.017 (0.009,0.025) 0.692 0.945 (0.922,0.969) 
      
POMC (2)      
rs6713532 25238337 0.656 0.027 (-0.095,0.149) 0.452 0.952 (0.663,1.367) 
rs3769671 25243657 0.500 0.059 (-0.102,0.219) 0.373 1.274 (0.804,2.021) 
rs6545976 25248154     
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Locus (Chr #) Base Position 
Class 
Membership Class Placement Beta (95% CI) Dependence Dependence OR (95% CI) 
POMC (2)      
rs6719226 25249516 0.565 0.017 (0.009,0.025) 0.010 0.947 (0.924,0.971) 
      
OPRM1 (6)      
rs1799971 154402490 0.094 -0.033 (-0.146,0.080) 0.100 1.237 (0.895,1.710) 
rs510769 154403712 0.071 0.065 (-0.100,0.225) 0.463 1.294 (0.815,2.054) 
rs3778151 154435373 0.063 0.017 (0.009,0.025) 0.831 0.948 (0.923,0.972) 
rs483021 154439021 0.829 -0.010 (-0.119,0.099) 0.755 1.052 (0.773,1.433) 
rs562859† 154456266 0.662 0.066 (-0.095,0.227) 0.822 1.270 (0.801,2.014) 
rs660756 154457127     
rs650245 154470384 0.026 0.017 (0.009,0.025) 0.926 0.947 (0.924,0.971) 
rs558025 154483657 0.119 -0.011 (-0.146,0.124) 0.748 1.010 (0.674,1.514) 
rs10485058 154486907 0.832 0.060 (-0.103,0.223) 0.627 1.327 (0.831,2.119) 
rs548339 154502491 0.728 0.018 (0.010,0.026) 0.974 0.949 (0.926,0.973) 
rs569284 154506022 0.987 -0.018 (-0.126,0.090) 0.678 0.943 (0.692,1.285) 
rs2236256 154520132 0.325 0.060 (-0.101,0.221) 0.490 1.277 (0.805,2.027) 
rs1918760 154523859 0.683 0.017 (0.009,0.025) 0.933 0.947 (0.924,0.971) 
rs2281617 154529113 0.323 -0.001 (-0.116,0.115) 0.977 0.934 (0.664,1.312) 
rs6941251 154529669     
rs1998220 154548120     
rs9322451 154564353 0.719 0.057 (-0.104,0.218) 0.214 1.317 (0.826,2.100) 
rs9479791 154571206 0.376 0.017 (0.009,0.025) 0.663 0.947 (0.924,0.971) 
rs790266 154583595 0.248 0.031 (-0.106,0.168) 0.442 1.159 (0.789,1.703) 
rs2272381 154584183 0.758 0.064 (-0.096,0.225) 0.598 1.269 (0.800,2.013) 
rs9371781 154593899 0.929 0.017 (0.009,0.025) 0.338 0.947 (0.924,0.971) 
rs6935927 154602029 0.452 0.108 (-0.205,0.421) 0.578 1.578 (0.579,4.300) 
rs4314511 154607027 0.458 0.061 (-0.100,0.221) 0.144 1.277 (0.805,2.025) 
      
PNOC (8)      
rs2722897 28229116 0.958 0.017 (0.009,0.025) 0.617 0.947 (0.924,0.971) 
rs1563945 28230805     
rs7825480 28234932 0.705 0.073 (-0.175,0.321) 0.590 2.993 (1.301,6.888) 
rs2614095 28240910 0.122 0.059 (-0.101,0.220) 0.116 1.271 (0.798,2.024) 
rs351776 28247225 0.352 0.017 (0.009,0.025) 0.169 0.948 (0.924,0.972) 
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Locus (Chr #) Base Position 
Class 
Membership Class Placement Beta (95% CI) Dependence Dependence OR (95% CI) 
PNOC (8)      
rs4732849† 28249765 0.076 -0.159 (-0.345,0.027) 0.119 1.540 (0.921,2.576) 
rs351784 28253666 0.483 0.064 (-0.097,0.225) 0.816 1.262 (0.793,2.008) 
rs4732850 28254635 0.604 0.017 (0.009,0.025) 0.282 0.948 (0.925,0.972) 
      
OPRK1 (8)      
rs3802280 54303552     
rs3802281 54303716 0.935 -0.114 (-0.238,0.010) 0.103 0.879 (0.622,1.241) 
rs7817710 54305368 0.292 0.051 (-0.109,0.211) 0.130 1.317 (0.829,2.094) 
rs7016275 54312323 0.255 0.017 (0.009,0.025) 0.292 0.946 (0.923,0.970) 
rs16918909 54312587 0.905 -0.136 (-0.278,0.007) 0.347 0.957 (0.639,1.433) 
rs7016778 54312658 0.217 0.059 (-0.101,0.219) 0.592 1.27 (0.801,2.014) 
rs1365097† 54315344 0.390 0.017 (0.009,0.025) 0.419 0.947 (0.924,0.971) 
rs6473797 54315535 0.574 0.028 (-0.229,0.285) 0.416 0.891 (0.430,1.845) 
rs6473798† 54315658 0.910 0.061 (-0.100,0.221) 0.855 1.290 (0.812,2.050) 
rs7826614 54319979 0.628 0.017 (0.009,0.025) 0.292 0.946 (0.923,0.970) 
rs10504151 54320793 0.861 -0.026 (-0.145,0.0921) 0.272 0.962 (0.685,1.350) 
rs3808627 54327355 0.852 0.039 (-0.128,0.206) 0.099 1.366 (0.846,2.205) 
      
PENK (8)      
rs1437277 57519288     
rs1975285 57521236 0.285 0.019 (0.010,0.027) 0.666 0.949 (0.924,0.974) 
rs2609998 57522588 0.910 -0.206 (-0.387,-0.025) 0.894 0.975 (0.579,1.645) 
      
PDYN (20)      
rs910080† 1908226 0.010 0.064 (-0.096,0.223) 0.297 1.259 (0.793,1.999) 
rs10485703 1908313     
rs6045824 1909977     
rs6035222 1911413 0.148 0.017 (0.009,0.025) 0.649 0.947 (0.923,0.970) 
rs1418038† 1914947 0.563 0.098 (-0.025,0.221) 0.418 1.059 (0.746,1.502) 
rs13037430† 1915049 0.427 0.054 (-0.107,0.215) 0.184 1.279 (0.806,2.028) 
rs2235751 1917934 0.074 0.017 (0.009,0.025) 0.278 0.948 (0.924,0.971) 
rs2235753† 1918547 0.376 0.016 (-0.131,0.162) 0.760 1.112 (0.725,1.706) 
rs2281285 1920460     
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Locus (Chr #) Base Position 
Class 
Placement Class Placement Beta (95% CI) Dependence Dependence OR (95% CI) 
PDYN (20)      
rs1997794 1922858 0.018 0.062 (-0.099,0.223) 0.663 1.289 (0.812,2.044) 
rs3830064 1923679 0.261 0.017 (0.009,0.025) 0.189 0.947 (0.924,0.971) 
rs7272891† 1924818 0.413 0.020 (-0.092,0.132) 0.396 1.005 (0.731,1.383) 
rs10854244† 1925045 0.111 0.060 (-0.101,0.220) 0.137 1.281 (0.808,2.031) 
rs6136667 1926301     
      
OPRL1 (20)      
rs6011280† 62175584 0.080 0.017 (0.009,0.025) 0.634 0.947 (0.923,0.970) 
rs6090041 62183120 0.705 -0.002 (-0.262,0.258) 0.692 1.164 (0.568,2.389) 
rs6512305 62186714     
rs6090043 62188374     
rs6011291 62193155     
rs7271530 62198359 0.478 0.070 (-0.091,0.231) 0.837 1.247 (0.785,1.980) 
rs6089789 62202436 0.854 0.017 (0.009,0.025) 0.056 0.947 (0.924,0.971) 
  42 
Discussion 
 
 Nothing definitive came from the single-marker association analyses, and only one SNP 
seemed to have a significant effect in the alcohol-related phenotypes.  An effect was detected in 
rs6719226, upstream from the coding region of POMC, on the presence of other substance 
dependence.  The SNP appears to have been studied in other substance use in only one study, 
which indicated no significant effect on either AD or other substance dependence, although 
sample size may have been a factor (Zhang et al, 2009).  The effect observed here seems to 
indicate that the minor allele of this SNP greatly increases the risk of alcoholics who initiate drug 
use to develop other substance dependence.  Considering that comorbidity of substance use 
disorders is common in AD, this result may not be surprising.  Since ethanol has been seen to 
change release of beta-endorphin, it could be that having this particular variant may in some way 
affect beta-endorphin expression such that rewarding sensations induced by drug use are 
heightened.  Experiments would have to be performed in order to determine if there is a real 
effect.   
 Four SNPs, while not found to be significant after corrective tests, suggest some trends.  
Two SNPs of PDYN, rs1997794 in the promoter of the gene and rs910080 in the 3′ UTR, showed 
a tendency toward the mild class.  Even though this was not determined to be a significant 
relationship, results from the regression on mild class probabilities indicate there might actually 
be one.  Those two SNPs as well as two others (rs10854244 and rs2235751) in PDYN seemed to 
show increased probabilities of belonging to the mild class.  These SNPs only resulted in a 
  43 
permuted p-value of 0.063, but perhaps there is an effect on the alcoholism phenotype.  It may be 
that the nature of the LCA reduced the power to fully detect such effects in PDYN.  With there 
being 12 different traits included, it would not be possible to determine if PDYN may buffer an 
individual from a more severe form of AD as a whole or if the trend reflects an impact on a 
specific characteristic more typical of a milder case.  The study in which the Collaborative Study 
on the Genetics of Alcoholism found associations of SNPs in PDYN with AD showed significant 
results for rs1997794, rs10854244, and rs910080 but not rs2235751 (Xuei et al, 2006).  
Furthermore, experiments showed increased levels of PDYN mRNA in convulsion-prone mice 
during a withdrawal period from ethanol but no difference in convulsion-resistant mice (Beadles-
Bohling and Wiren, 2005).  In addition, having alleles containing 3 or 4 repeats in a 68-bp repeat 
in the PDYN promoter may protect against or decrease risk for cocaine dependence (Chen et al, 
2002).  These previous studies in conjunction with the results presented here indicate that SNPs 
in PDYN could affect expression of the gene to impact severity of alcohol and/or other substance 
dependence.  Expression studies can confirm if these SNPs would affect expression levels, and in 
vivo studies of these SNPs could indicate if they affect severity of dependence.  Assocation 
studies of these SNPs with each of the indicators from the LCA may also help to determine how 
PDYN may affect dependence severity.  
The two SNPs in the intronic region of OPRD1 (rs529520 and rs3766951) seem 
interesting as well.  Zhang, et al. found no significant effects of rs529520 on alcohol or drug 
dependence but did report an effect of rs421300, which tags rs3766951, on those features (Zhang 
et al, 2008).  There is evidence that delta receptor subtypes oppositely affect consumption of 
alcohol (van Rijn and Whistler, 2009).  Anti-depressant and anti-convulsive effects of delta 
receptor activation could suggest a role in the behavioral side effects and physiological responses 
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to intoxication (Jutkiewicz 2006).  If these SNPs had been shown to be significant here, it could 
be suggested that they may affect downstream expression of the receptor subtypes to mediate a 
person’s response to alcohol.   
The IASPSAD offered terrific advantages to this study.  Ireland is a fairly homogeneous 
population that did not see heavy immigration into the country until the mid-1990s when the 
country joined the European Union.  Considering over 36 million Americans claim Irish descent, 
and millions also claim heritage from genetically similar populations from nearby Ireland, the 
results do have implications in this country.  Because this is a clinical sample, the cases tended to 
be much more severe, which is ideal for finding susceptibility loci even of small effects sizes.  
The reliability of the interviews and the large collection of data provide a good basis for studying 
a variety of phenotypes.  While the analyses conducted here were across non-related individuals, 
the IASPSAD contains information and DNA from many parents and affected relatives.  This 
could allow for more in-depth family-based examinations of opioid gene variants in future 
studies.   
 One disadvantage here is the fact that the use of more clinically severe patients may not 
translate well into the general population, which may carry susceptibility loci of smaller effects 
sizes that contribute to milder states of AD.  Since the DSM-IV considers AD and AA mutually 
exclusive, the results here may not apply to “problem drinkers,” although there is probably good 
etiological overlap between dependence and abuse.  Due to funding and collection methods, 
phenotypic information has only been collected from affected individuals, so analyses of the 
IASPSAD only apply to variation within alcohol dependence.  The drug dependence phenotypes, 
while fairly inclusive, pose an issue.  Until the mid-1990s before the IASPSAD was conducted, 
lower drug trafficking and availability did put limits on the substances people could potentially 
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use.  For this reason, dependence on certain groups of drugs such as opioids was much rarer in 
these samples, and explains why fewer of the cases had comorbid drug dependence than would 
be expected for similar studies in the US; therefore, drug specific analyses are not appropriate to 
use in this sample.    
Given the amount of evidence in the literature, it would have been expected to find 
several significant associations of SNPs within the opioid genes.  The most likely reason for the 
lack of findings is insufficient power.  Alcohol dependence is a very heterogeneous disease, and 
the phenotypes used here can be quite variable, even though the affected individuals in the 
samples tended to be more severely affected.  Using the free software Quanto (version 1.2.4, 
University of Southern California), it was calculated that for binary association tests using a 
sample size of 537 (such as the simple case-control analysis), assuming a MAF=0.2 and 
significance level of 0.05, the power to detect loci contributing odds ratios of 1.2 is only 29.4%.  
The power from the substance dependence analyses would therefore be even lower.  For 
analyzing the alcohol-related traits, class membership and probabilities, the power to detect in a 
sample of 537 individuals a beta effect size of 0.8 under the same assumptions is only 31.8%.  
The effects sizes of each SNP were likely too low to be detected here.  The possibility of the 
false positive in dependence cannot be completely excluded, but given the molecular evidence 
that the opioid receptor system is involved in the development of addictions, it is very unlikely 
that rs6719226 is not involved in drug dependence in alcoholics, nor is it very likely that some of 
the negative findings really are negative. 
 Another limitation is that the analyses are not entirely inclusive.  The search for 
additional tagging SNPs was restricted to the intronic and exonic regions.  Changes in non-
coding regions can have an impact on transcription and translation, so information may have 
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been lost by not expanding the search.  There is growing research into extragenic variants, which 
are increasingly being studied in the genetics of complex behaviors, in the opioid genes.  In 
several inbred mouse strains, short tandem repeat polymorphisms in the 5′ and 3′ UTRs of the 
mu receptor gene were found to be correlated with morphine-induced antinociception (Shigeta et 
al, 2008).  There is also a purported complex indel in the promoter region for OPRK1 (Edenberg 
et al, 2008).  The opioid receptor system appears to be larger than the classical set of genes used 
here.  Recently it has been shown that human OPRM1 may be twice as large as is currently 
known (Shabalina et al, 2009).  Strong homology to the opioid receptors and involvement in 
feeding behavior and antinociception suggest that the G protein-coupled receptors 7 and 8 
(GPR7 and GPR8, respectively) are also part of the system (Dreborg et al, 2008; Shimomura et 
al, 2002; Tanaka et al, 2003).  In addition, zinc ectopeptidases, modulators of enkephalin-related 
activity, and the endogenous Opiorphin, which inhibits two such ectopeptidases, demonstrate 
that there are mechanisms specific for opioid receptor control (Wisner et al, 2006). 
Gene-gene and gene-environment interactions were not considered in the analyses.  This 
can pose a limitation.  Conducive environments play a major part in the expression of genetic 
susceptibility, but little information (childhood abuse, stressful life events surrounding periods of 
drinking or substance use, religious influences, etc) was collected in the IASPSAD to perform 
GxE analyses.  Future studies may want to study interactions between SNPs in the opioid 
receptor genes and SNPs in other neurotransmitter receptor genes, such as the cannabinoid and 
dopamine receptors, because of the molecular evidence of receptor interactions.      
Due to reduced power, a strong genetic role of the opioid receptor system in alcohol 
dependence could not be verified, but the results did find an effect in dependence and suggest 
other possible effects for future studies.  Future endeavors should also include flanking regions 
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of the opioid genes with molecular experiments to determine that signals are coming from the 
genes of interest and to further clarify the role of suspected loci.   
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Figure 3. Example plot of VIC and FAM fluorescences from genotyping of rs499062 in OPRD1.  Every 96 
wells are represented in a graph of the fluorescences.  The three linearized clusters to the upper right 
represent the three possible genotypes for this SNP, and the bottom left cluster represents the wells in which 
clear amplification was unsuccessful. 
 
 
 
 
Figure 4. Plots of VIC and FAM fluorescences from genotyping rs6011280 in OPRL1.  The graph to the left 
depicts partial results from the standard PCR protocol that was seen across all plates.  The figure to the right 
shows results from the modified protocol.  Both figures show fluorescence plots from the same DNA samples. 
 
 
